Press release
Huateng Pharma Unveils Cutting-Edge Gastrointestinal API Intermediates
Huateng Pharma, a renowned name in the pharmaceutical industry, is proud to introduce a groundbreaking addition to its product portfolio - Gastrointestinal API Intermediates. This new line features the highly anticipated Fexuprazan Intermediate and Vonoprazan Intermediates, designed to empower pharmaceutical manufacturers with top-tier solutions.The Fexuprazan Intermediate, boasting the chemical compound Methyl 5-(2,4-Difluorophenyl)-4-methoxypyrrole-3-carboxylate (CAS NO. 1902955-29-6), and the Vonoprazan Intermediates, which include 5-(2-Fluorophenyl)-1H-pyrrole-3-carbaldehyde (CAS NO.: 881674-56-2) and Pyridine-3-sulfonyl chloride (CAS NO.: 16133-25-8), represent a leap forward in gastrointestinal therapy.
Sonia, Huateng Pharma's Marketing Director, underscores the significance of this new product line, stating, "Our Gastrointestinal API Intermediates are a testament to our commitment to innovation and excellence. We are excited to offer pharmaceutical manufacturers a range of products that can truly make a difference."
Huateng Pharma's dedication to quality and client satisfaction is evident in the availability of GMP (Good Manufacturing Practice) and Non-GMP grade options for these intermediates. These intermediates are characterized by their exceptional purity, ensuring that clients have access to the highest quality materials for their pharmaceutical production needs.
Sonia continues, "We understand the diverse needs of our clients in the pharmaceutical industry. By offering both GMP and Non-GMP grade intermediates with high purity, we aim to equip our clients with the tools they need to excel in their endeavors."
The introduction of these Gastrointestinal API Intermediates reflects Huateng Pharma's ongoing commitment to providing superior solutions for pharmaceutical manufacturers. By utilizing these intermediates, manufacturers can create innovative and impactful gastrointestinal medications that benefit patients worldwide.
To learn more about Huateng Pharma's Gastrointestinal API Intermediates and their comprehensive range of pharmaceutical ingredients, please visit us.huatengsci.com or contact sales@huatengusa.com for further details.
About Huateng Pharma:
Huateng Pharma is a renowned pharmaceutical ingredient manufacturer dedicated to delivering high-quality ingredients to the global pharmaceutical and biotech industries. With a focus on research, development, and quality assurance, Huateng Pharma is at the forefront of providing essential solutions for the production of life-changing medications.
Hunan Huateng Pharmaceutical Co., Ltd.
Headoffice: Building E1, Lugu Corporation Plaza, High-Tech Industrial Development Zone, Changsha City, Hunan Province, P.R.China
Website: https://us.huatengsci.com
Email: sales@huatengusa.com
Sonia Lee
Huateng Pharma has unveiled its new Gastrointestinal API Intermediates, including Fexuprazan and Vonoprazan intermediates, offering both GMP and Non-GMP grade options with exceptional purity to empower pharmaceutical manufacturers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Huateng Pharma Unveils Cutting-Edge Gastrointestinal API Intermediates here
News-ID: 3251999 • Views: …
More Releases from Hunan Huateng Pharmaceutical Co., Ltd.
Huateng Pharma Introduces New Cosmetic Actives to Meet Growing Demand for High-P …
Huateng Pharma, a global leader in specialty chemicals, has expanded its product portfolio to include a new line of high-quality cosmetic ingredients. The launch addresses the increasing demand for effective, safe, and readily available actives for modern skincare and personal care formulations.
The new offerings are now available for immediate delivery and include several key ingredients:
Diethylamino Hydroxybenzoyl Hexyl Benzoate (CAS 302776-68-7): A REACH-registered UVA filter that provides broad-spectrum sun protection. This…
Huateng Pharma Highlights the Pharmaceutical Potential of N-Benzylhydroxylamine …
Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This compound has gained attention for its multifunctional properties and critical role in drug discovery and development.
N-Benzylhydroxylamine Hydrochloride features a unique nitrogen-oxygen (N-O) functional group, which enables its wide-ranging applications in medicinal chemistry, including:
Metal Chelation for Iron Overload Disorders: Its…
Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CP …
Changsha, China - 18 March 2025 - Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and cutting-edge capabilities at Booth No. 4X-06, located at Tokyo Big Sight, Tokyo, Japan, from April 9th to 11th, 2025.
Huateng Pharma is dedicated to providing robust support…
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Changsha, China - Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma's dedication to meeting the highest regulatory standards and further strengthens its commitment to supporting…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
